Title: Recent human metapneumovirus genomic diversity within expected evolutionary trends

Stephanie Goya PhD [1], B. Ethan Nunley B.S. [1], Preston C. Longley B.S. [1], Jamie R. Mathis B.S. [2], Christina G. Varela B.S. [1], Da Yae Kim B.S.[1], Marc Nurik M.B.S. [2], Samia N. Naccache PhD [2], Alexander L. Greninger MD [1,3,#]

Affiliations:

[1] Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98109, USA

[2] LabCorp, Seattle, WA 98122, USA

[3] Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA

[#]Corresponding author.

Email address: agrening@uw.edu

Running title: HMPV genomic epidemiology

Keywords: human metapneumovirus, genome, USA, China, surveillance, sublineage, A2b2, B2.

Abstract

In December 2024, human metapneumovirus (hMPV) gained international attention due to concerns over increases in cases in Chinese hospitals, leading the World Health Organization (WHO) to issue a statement indicating case numbers were within expected ranges. To assess potential variant emergence, 99 hMPV genomes, including 13 recent cases from November 2024 to January 2025, were sequenced from symptomatic patients in western Washington State. Phylogenetic analysis identified co-circulating sublineages, with A2b2 (containing a 111 nt duplication in the attachment glycoprotein G) being the most prevalent. Recent hMPV genomes did not form a single monophyletic group, indicating ongoing introductions and diverse variant circulation within sublineages. hMPV sublineages exhibit strong temporal signal and similar evolutionary rates, and particularly the faster-evolving A2b2-111dup lineage (1.1×10^{-3} substitutions/site/year), but no evolutionary features of heightened concern were detected. hMPV seasonal circulation and continuous evolution should be monitored closely, especially as vaccine trials are underway.

Research Letter

In December 2024, human metapneumovirus (hMPV) gained international attention due to concerns over increases in cases in Chinese hospitals, leading the World Health Organization (WHO) to issue a statement indicating case numbers were within expected ranges[1]. Discovered in 2001, hMPV is a seasonal pathogen that causes mild respiratory diseases but can lead to severe outcomes like bronchiolitis and pneumonia, especially in infants, the elderly, and immunocompromised individuals[2]. hMPV remains a global health threat, responsible for an estimated 643,000 annual hospitalizations and 7,700 deaths in children under 5. Timely efforts for a combined mRNA vaccine against hMPV and respiratory syncytial virus (RSV) in children are progressing promisingly[3]. However, our understanding of hMPV's genomic epidemiology remains extremely limited; for instance, only 111 hMPV genomes were deposited in NCBI GenBank in 2024, compared to over 5,000 RSV genomes (Figure 1A).

To identify whether hMPV is undergoing variant emergence of concern for public health, we sequenced hMPV genomes collected from 2021 to 2025 from symptomatic inpatients and outpatients from all age groups in western Washington State, a key region for detecting early spread of SARS-CoV-2 from China (Appendix). We obtained 60 hMPV-A and 39 hMPV-B, including 13 recent hMPV from November 2024–January 2025 (Figure 1B). We observed co-circulation of four sublineages: A2b1, A2b2 (containing the 111 nt duplication in the attachment glycoprotein G) within hMPV-A, and B1 and B2 within hMPV-B[4]. The A2b2 lineage was the most prevalent, followed by B2 (Figure 1B).

No significant differences in gender or age group were found across sublineages or annual outbreaks. Only outpatients were detected in the recent hMPV group. Phylogenetic analysis showed that recent hMPV did not cluster into a single monophyletic group, indicating ongoing introductions to Washington State and circulation of diverse variants within each sublineage (Figures 1C-D). The recent hMPV genomes followed the expected evolutionary divergence pattern, consistent with no emergence of a new variant. Global data indicates that most hMPV sublineages exhibit a notable temporal signal, with slight variations in their evolutionary rates. In particular, the A2b2-111dup lineage evolves faster, at 1.1×10^{-3} substitutions per site per year.

These findings suggest that hMPV circulation in the USA is consistent with patterns observed for other respiratory viruses, driven by the continuous introduction of pre-existing sublineages. On a global scale, hMPV does not exhibit any distinctive genomic features that warrant heightened concern, but its seasonal circulation and continuous evolution should be monitored closely, especially as vaccine trials are underway.

Disclaimers

ALG reports contract testing from Abbott, Cepheid, Novavax, Pfizer, Janssen, Hologic.

Data Availability

hMPV consensus genomes are available at NCBI GenBank under the accession numbers PV052133-PV052231. Sequencing reads are available associated with NCBI BioProject PRJNA1027483. Supplementary Table 1 details the hMPV specimen metadata and including accession numbers to NCBI. Phylogenetic trees are available on https://github.com/greninger-lab/MPV_genomics.

Bibliography

1 Wang X, Li Y, Deloria-Knoll M, *et al.* Global burden of acute lower respiratory infection associated with human metapneumovirus in children under 5 years in 2018: a systematic review and modelling study. *Lancet Glob Health* 2021; **9**: e33–43.

2 Shafagati N, Williams J. Human metapneumovirus - what we know now. *F1000Res* 2018; **7**: 135.

3 ModernaTX, Inc. A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months. clinicaltrials.gov, 2024 https://clinicaltrials.gov/study/NCT05743881.

4 Saikusa M, Nao N, Kawakami C, *et al.* A novel 111-nucleotide duplication in the G gene of human metapneumovirus. *Microbiol Immunol* 2017; **61**: 507–12.

Figure 1. Human metapneumovirus genomic epidemiology. A) Number of hMPV genomes available in NCBI GenBank by year of sample collection. Genomes are categorized by hMPV subgroup: hMPV-A and hMPV-B. New genomes from Washington State (WA) are highlighted. B) Frequency of hMPV sublineages by month of sample collection in WA. The total number of genomes analyzed is indicated at the top of each bar. C) and D) Timetree of hMPV-A and hMPV-B, respectively. Colors in the branches represent hMPV sublineages. Dots at the end of the branches indicate whether the new genomes are from this study (red) or from GenBank (gray). A dotted line denotes year 2020 in both trees. On the left of each tree, the root-to-tip divergence (y-axis) versus the collection date (x-axis) for the entire phylogenetic tree (Global) and for each sublineage, including the estimated evolutionary rate and the R^2 value. The tree scale and the rate estimation are substitutions/site/year. Details of the methodology are provided in the appendix.


A
Available hMPV genomes
Group
A
A (WA)
B
B (WA)
B
Subtype frequency in WA
Sublineage
B1
B2
A2b1
A2b2 (111dup)
C
hMPV-A
root-to-tip divergence
Collection year
Rate
R2
Global 9.5 x 10-4 0.95
A1 9.2 x 10-4 0.85
A2a 7.9 x 10-4 0.87
A2b1 8.6 x 10-4 0.92
A2b2 7.4 x 10-4 0.67
A2b2 (111dup) 1.1 x 10-3 0.91
A2b2 (180dup) 5.5 x 10-4 0.46
D
hMPV-B
Global 7.8 x 10-4 0.92
B1 9.6 x 10-4 0.97
B2 6.8 x 10-4 0.93